Attached files
| file | filename |
|---|---|
| EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER REQUIRED BY SECTION 302 - Oncotelic Therapeutics, Inc. | d330877dex311.htm |
| EX-10.1 - OFFER LETTER TO DAVID L. JOHNSON - Oncotelic Therapeutics, Inc. | d330877dex101.htm |
| EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER REQUIRED BY SECTION 302 - Oncotelic Therapeutics, Inc. | d330877dex312.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Oncotelic Therapeutics, Inc. | Financial_Report.xls |
| 10-Q - FORM 10-Q - Oncotelic Therapeutics, Inc. | d330877d10q.htm |
Exhibit 32.1
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officers of OXiGENE, Inc. (the “Company”), do hereby certify, to such officers’ knowledge, that:
The Quarterly Report on Form 10-Q for the three months ended March 31, 2012 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: May 11, 2012 | By: | /s/ Peter J. Langecker | ||||
| Peter J. Langecker | ||||||
| Chief Executive Officer | ||||||
| Date: May 11, 2012 | By: | /s/ David L. Johnson | ||||
| David L. Johnson | ||||||
| Chief Financial Officer | ||||||
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.